GlassScriptPhysician profile
Bianca Ummat
NPI 1538459839
$7,098.38
in general payments reported to CMS, 2019-2025
29 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $122 · 2021: $276 · 2022: $367 · 2023: $2,366 · 2024: $491 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,144 · Travel and Lodging: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,144.44 |
| Travel and Lodging | $1,355.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,231.50 | 2019-2023 | Optis, Pressurewire, Dragonfly Opstar |
| Boston Scientific Corporation | $1,423.41 | 2019-2025 | General - Vascular Access, Avvigo Guidance System, Ekosonic |
| Terumo Medical Corporation | $368.01 | 2019-2025 | Metacross Otw |
| E.R. Squibb & Sons, L.L.C. | $344.56 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $329.60 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $315.30 | 2019-2025 | |
| Inari Medical, INC. | $167.02 | 2019-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $157.19 | 2021-2023 | Brilinta |
| Asahi Intecc USA, INC. | $142.16 | 2024 | Peripheral Vascular |
| Stryker Corporation | $67.57 | 2025 | Flowtriever, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic, INC. | $58.52 | 2024 | Symplicity G3 |
| Novo Nordisk INC | $48.98 | 2019-2025 | Rybelsus, Ozempic |
| Abiomed | $48.85 | 2022 | |
| Amgen INC. | $43.24 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.45 | 2024-2025 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $36.02 | 2022-2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $35.50 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $34.97 | 2022-2023 | Arcalyst |
| Atricure, INC. | $30.86 | 2023-2024 | |
| Astellas Pharma US INC | $30.45 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $23.38 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $21.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.13 | 2020 | |
| Edwards Lifesciences Corporation | $18.21 | 2019 | |
| Merck Sharp & Dohme LLC | $17.95 | 2025 | Verquvo |
| Genzyme Corporation | $14.73 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.27 | 2019 | |
| Elutia, INC. | $10.52 | 2019 | |
| Cardiovascular Systems INC. | $9.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bianca Ummat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.